hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06344247, orgStudyIdInfo id: IIT-2023-0253, briefTitle: Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA).Eligible patients were randomly and non-blindly allocated to four groups in a 1:1:1:1 ratio.The first group is the optimized treatment group, and patients in this group maintain the maximum dose/maximum tolerated dose of RAS blocker therapy.The second group is the optimized treatment + SGLT2i group. Participants in this group are titrated to the target dose (10 mg qd) in combination with dapagliflozin on the basis of optimized treatment.The third group is the optimized treatment + GLP-1RA group. Participants in this group will be titrated to the target dose (1mg qw) in combination with semaglutide on the basis of optimized treatment.The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw)., conditionsModule conditions: Obesity, conditions: Chronic Kidney Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: RAS inhibitors：Losartan®️/Valsartan®️, interventions name: dapagliflozin：Forxiga®️, interventions name: simagliptin：Forxiga®️, outcomesModule primaryOutcomes measure: Change of 24-hour urine protein quantification, secondaryOutcomes measure: Decline in glomerular filtration rate, secondaryOutcomes measure: Changes in BMI, secondaryOutcomes measure: changes in fasting blood glucose, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Renji Hospital Affiliated to Shanghai JIAO TONG University school of medicine, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200127, country: China, contacts name: wei jin, role: CONTACT, phone: +8615026696535, email: jinwei_xj@126.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06344208, orgStudyIdInfo id: IEO 1647, briefTitle: Predicting Toxicity in Elderly Patients With Head and Neck Cancer, acronym: PREtoxEL, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-15, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: Predicting toxicity in elderly patients with head and neck cancer:validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes., conditionsModule conditions: Head and Neck Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3, type: ESTIMATED, outcomesModule primaryOutcomes measure: Predicting toxicity in elderly patients with head and neck cancer, eligibilityModule sex: ALL, minimumAge: 70 Years, maximumAge: 99 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, state: MI, zip: 20141, country: Italy, contacts name: maria Cossu Rocca, MD, role: CONTACT, phone: 00390294372900, email: maria.cossurocca@ieo.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06344195, orgStudyIdInfo id: 2517, briefTitle: Valacyclovir Monotherapy in Pain Management of Acute Periapical Abscesses After Emergency Chamber Opening, acronym: Antiviral, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Dow University of Health Sciences, class: OTHER, descriptionModule briefSummary: This study is aimed to evaluate the efficacy of valacyclovir in reducing postoperative pain following emergency chamber opening for acute apical abscess .There will be 82 participants, (41 in each group) Group A will receive Valacyclovir Group B will receive standard treatment i.e. Naproxen Sodium. Pain level will be assessed by using Numeric rating scale for 6 days, conditionsModule conditions: Acute Apical Abscess, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 82, type: ESTIMATED, armsInterventionsModule interventions name: Valacyclovir 500 mg, interventions name: Naproxen Sodium 550mg, outcomesModule primaryOutcomes measure: Changes in pain score using Numeric Rating Scale (NRS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dr. Yumna Shaheen Ali, status: RECRUITING, city: Karachi, state: Sindh, zip: 75290, country: Pakistan, contacts name: Dr. Yumna Shaheen Ali, role: CONTACT, email: yumna.shaheen@duhs.edu.pk, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06344182, orgStudyIdInfo id: STarkan, briefTitle: Reliability, Concurrent Validity and Minimal Detectable Change of the Step Up and Down Test in Patients With Total Knee Arthroplasty, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-02-01, primaryCompletionDateStruct date: 2021-05-15, completionDateStruct date: 2021-05-15, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Dokuz Eylul University, class: OTHER, descriptionModule briefSummary: The aim of the study is to measure the validity and reliability of the StUD test in patients with TKA. Forty-seven patients with primary TKA included in this study. The test-retest reliability of the StUD test was measured with 1-hour interval. Validity was assessed that the 30s Chair Stand Test (30sCS), the Hospital for Special Surgery score (HSS) and Short Form-12 Quality Life Questionnaire (SF-12) were used as comparator instruments., conditionsModule conditions: Total Knee Arthroplasty, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 47, type: ACTUAL, armsInterventionsModule interventions name: Step Up and Down Test, outcomesModule primaryOutcomes measure: Step Up and Down Test, secondaryOutcomes measure: 30 Seconds Chair Stand Test, otherOutcomes measure: Hospital for Special Surgery (HSS) Knee Score, otherOutcomes measure: 12-Item Short-Form Health Survey, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dokuz Eylul University, city: Izmir, country: Turkey, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06344156, orgStudyIdInfo id: PDAC-Neoantigen, briefTitle: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Sichuan University, class: OTHER, descriptionModule briefSummary: The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer, conditionsModule conditions: Pancreatic Cancer, conditions: Adjuvant Therapy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 43, type: ESTIMATED, armsInterventionsModule interventions name: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy, outcomesModule primaryOutcomes measure: 18-month RFS, primaryOutcomes measure: Incidence of Treatment-Related Adverse Events [Safety and Tolerability], secondaryOutcomes measure: 18-month OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: West China Hospital, Sichuan University, status: RECRUITING, city: Chengdu, state: Sichuan, zip: 610000, country: China, contacts name: Zhong Wu, MD, role: CONTACT, phone: 028-85422851, email: wuzhong5555@126.com, contacts name: Zhong Wu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06344143, orgStudyIdInfo id: 24-324, briefTitle: Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma, acronym: MACS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2029-11-01, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, collaborators name: Recordati Rare Diseases, descriptionModule briefSummary: The aim of the proposed study is to estimate the incidence of Mild Autonomous Cortisol Secretion (MACS) in patients with Adrenal Incidentaloma (AI) and evaluate the available diagnostic tests to determine the most sensitive and specific combination of tests for assessing MACS from adrenal adenoma for prediction of the phenotype associated with cortisol excess. As well as following the patients for 4 years and see if anything changes., conditionsModule conditions: Mild Autonomous Cortisol Secretion (MACS), designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Various labs and imaging tests, outcomesModule primaryOutcomes measure: Evaluate best diagnostic test(s), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Cleveland Clinic Foundation, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Maya Boyd, role: CONTACT, phone: 216-444-4919, email: boyda5@ccf.org, contacts name: jenkink@ccf.org Jenkins, role: CONTACT, phone: 216-445-4791, email: jenkink@ccf.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06344117, orgStudyIdInfo id: MF3 UHN (IA), briefTitle: Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients, acronym: UHN, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-12, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Owlstone Ltd, class: INDUSTRY, descriptionModule briefSummary: Prospective observational pilot study to evaluate the utility of breath VOCs to detect invasive aspergillosis in lung transplant recipients that are suspected of invasive fungal disease (IFD)., conditionsModule conditions: Invasive Aspergillosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Identifying a statistical relationship between Volatile Organic Compounds detection and the diagnosis of IA by existing International Society for Heart and Lung Transplantation (ISHLT) and MSG/EORTC criteria., secondaryOutcomes measure: Identifying a statistical relationship between the set of VOCs found in exhaled breath and the diagnosis of Aspergillus colonization as defined by ISHLT criteria, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Health Network, status: RECRUITING, city: Toronto, state: Ontario, zip: M5G 2N2, country: Canada, contacts name: Shahid Husain, MD,MS, role: CONTACT, phone: (416) 340-3144, email: shahid.husain@uhn.ca, contacts name: Shahid Husain, MD,MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06344091, orgStudyIdInfo id: ZYWB-ZM-AHP-A-003, briefTitle: A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-06, primaryCompletionDateStruct date: 2026-09-28, completionDateStruct date: 2026-10-12, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Jiangsu HengRui Medicine Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world., conditionsModule conditions: Local Analgesia Via Infiltration, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: A single-arm study of liposomal bupivacaine injection, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 232, type: ESTIMATED, armsInterventionsModule interventions name: Bupivacaine Liposome Injection, outcomesModule primaryOutcomes measure: The incidence of Treatment Emergent Adverse events (TEAE) in the cardiac and nervous system, secondaryOutcomes measure: The cumulative amount of opioids used in 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration, secondaryOutcomes measure: Time to first rescue analgesia of opioid, secondaryOutcomes measure: The proportion of patients who did not use rescue analgesia during 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration, secondaryOutcomes measure: The proportion of patients using patient-controlled intravenous analgesia (PCIA), secondaryOutcomes measure: Pain intensity score at rest after administration for children aged 6 to 7 years, secondaryOutcomes measure: Pain intensity score at rest after administration for children aged 8 years and older, secondaryOutcomes measure: Pain intensity score on movement (or cough) after administration for children aged 6 to 7 years, secondaryOutcomes measure: Pain intensity score on movement (or cough) after administration for children aged 8 years and older, secondaryOutcomes measure: Length of Stay, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Guangzhou Women and Children's Medical Center, city: Guangzhou, state: Guangdong, zip: 510000, country: China, contacts name: Xingrong Song, role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06344078, orgStudyIdInfo id: SIGMA-d, briefTitle: Surgical Italian Guide for the Management of Complicated Acute Diverticulitis Emergency Setting (SIGMA-D). A Prospective Observational Multicenter Study on Behalf of the Italian Society of Colorectal Surgery (SICCR)., acronym: SIGMA-D, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Societa Italiana di Chirurgia ColoRettale, class: NETWORK, descriptionModule briefSummary: This study will include data collected from surgical units performing emergency surgery in Italy during 2024, with a one-year follow-up period for each patient. Data for each center will be prospectively collected through a database filled out by the Italian Society of Colorectal Surgery (SICCR) members who participate to the study. Specific data will include: WSES diverticulitis classification, procedure timing, laparoscopic/converted procedures, rate of performed protection ileostomies or colostomies, rate and timing of Hartmann reversal or stoma closure, procedures with more than two operators, procedures with expert first operator, night or weekend procedures, and patients aged over 80. Postoperative data will focus on complication rates and mortality at one, six, and twelve months., conditionsModule conditions: Acute Diverticulitis, conditions: Stoma Colostomy, conditions: Stoma Ileostomy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: sigmoid resection and anastomosis / stoma, outcomesModule primaryOutcomes measure: adhesion to guidelines, secondaryOutcomes measure: stoma reversal, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azienda ospedaliera universitaria paolo giaccone, status: RECRUITING, city: Palermo, country: Italy, contacts name: francesco ferrara, medicine and surgery, role: CONTACT, phone: +393343035829, email: frr.fra@gmail.com, contacts name: claudio guerci, role: CONTACT, phone: +393473898094, email: guerci.clau@gmail.com, geoPoint lat: 38.13205, lon: 13.33561, hasResults: False
protocolSection identificationModule nctId: NCT06344065, orgStudyIdInfo id: 20220102C, briefTitle: Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-21, primaryCompletionDateStruct date: 2025-05-25, completionDateStruct date: 2028-12-25, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 1584, type: ESTIMATED, armsInterventionsModule interventions name: Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed), interventions name: Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), interventions name: Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine, outcomesModule primaryOutcomes measure: Immunogenicity results of experimental group and active control group (DTaP), primaryOutcomes measure: Immunogenicity results of experimental group and active control group (DTaP-IPV//PRP-T), primaryOutcomes measure: Immunogenicity results of experimental group, eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 3 Months, stdAges: CHILD, contactsLocationsModule locations facility: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, status: RECRUITING, city: Nanning, state: Guangxi, zip: 530028, country: China, contacts name: Yi Mo, role: CONTACT, phone: +86-13788686968, email: 13647272@qq.com, geoPoint lat: 22.81667, lon: 108.31667, hasResults: False
protocolSection identificationModule nctId: NCT06344039, orgStudyIdInfo id: Floating hip, briefTitle: Epidemiological Study of Floating Hip Injuries in Assiut University Hospitals, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Aim of the study is to describe and study the patterns of floating hip injuries and assess the current management in Assiut University Hospitals Trauma Centre to help reach the best approach to plan treatment for these severe and difficult injuries., conditionsModule conditions: Hip Fractures, conditions: Hip Injuries, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Incidence of floating hip injuries, primaryOutcomes measure: Patterns of injury, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06344013, orgStudyIdInfo id: 29BRC24.0034 - BUNDLE ABCDEF, briefTitle: The ABCDEF Bundle in Critical Care: a French National Survey Still a Long Way to go!, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-01, primaryCompletionDateStruct date: 2022-07-31, completionDateStruct date: 2022-07-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University Hospital, Brest, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to evaluate the knowledge and compliance of French intensive care units with the ABCDEF (A: Assessment, Prevention, Management of Pain, B: Both Spontaneous Awakening Trials and Spontaneous Breathing Trials, C: Choice of Sedation and Analgesia, D: Delirium Assessment, Prevention, and Management, E: Early Mobility and Exercise, F: Family Engagement and Empowerment) bundle. French ICU doctors will be asked to answer a questionnaire available online., conditionsModule conditions: Delirium, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 341, type: ACTUAL, outcomesModule primaryOutcomes measure: knowledge and compliance of French intensive care units with the ABCDEF, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chu Brest, city: Brest, zip: 29609, country: France, geoPoint lat: 48.3903, lon: -4.48628, hasResults: False